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Abstract:  Guest-host  complex  formation  of  three  drug  derivatives  of  anthranilic  acid, 
mefenamic acid, niflumic acid, and flufenamic acid with 2-hydroxypropyl-β-cyclodextrin 
(2HP-β-CD)  in  aqueous  solutions was  investigated  using  ―Phase  solubility  study‖  with 
UV-vis spectrophotometry. Solubility of sparingly soluble drugs has been improved by 
addition of 2HP-β-CD at two temperatures 298.15 K and 310.15 K and two pH values 2 
and  7.  The  influence  of  different  2HP-β-CD  concentration  on  solubility  of  drugs  at 
different  pH  and  temperatures  has  been  investigated.  The  2HP-β-CD-drug  complex 
stability constants (Ks), and dissociations constants (Kd), as well as the thermodynamic 
parameters of reaction, i.e., the free energy change (ΔG), the enthalpy change (ΔH) and the 
entropy change (ΔS), were determined. The experimental data indicated formation of 1:1 
inclusion complexes, which were found effective binders increasing the solubility of drugs. 
Keywords:  experimental  solubility;  2-hydroxypropyl-β-cyclodextrin;  solubility 
enhancement; thermodynamics of complex formation 
 
1. Introduction 
Cyclodextrins  (CDs),  the  natural  oligosaccharides  possessing  a  hydrophilic  exterior  and 
hydrophobic cavity, are well-known safe encapsulating materials [1–3]. In fact, new and promising 
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CDs are continually being examined for their ability to improve complexity in order to obtain both 
higher  solubility  of  drugs,  and  stabilizing  or  solubilizing  agents  [4–6].  The  mechanism  for  this 
solubilization is rooted in the ability of CDs to form non-covalent dynamic inclusion complexes in 
solution.  These  CDs  can  serve  as  multi-functional  drug  carries,  through  the  formation  of  these 
inclusion  complexes,  or  the  form  of  CD-drug  conjugate,  the  ability  to  form  non-inclusion  based 
complexes,  the  formation  of  aggregates  and  related  domains  and  the  ability  of  CDs  to  form  and 
stabilize supersaturated drug solutions and, thereby potentially serving as novel drug carriers. Thus, the 
investigation  on  inclusion  of  drug  with  CDs  is  of  practical  importance.  A  number  of  CD-based 
products have reached the market based on their ability to camouflage undesirable physicochemical 
properties. The hydroxypropyl derivatives of cyclodextrin are very often used in pharmacy due to their 
better  complexation  ability  than  that  of  natural  cyclodextrin  and  they  increase  the  solubility  and 
bioavailability more than natural cyclodextrin [4,7–13]. Different CDs including β-CD were used to 
complex formation with candesartan cilexetil showing the highest constant of complex formation for 
β-CD with large enthalpy effect [8]. The 2-hydroxypropyl-β-cyclodextrin (2HP-β-CD) demonstrated 
more stable complexes than other -, or -, or - complexes of menadione [4]. The 2HP-β-CD was 
used to enhance the solubility of acyl ester prodrugs of ganciclovir in water [7]. The 2HP-β-CD was 
used for the complexation of triclosan, an antimicrobial agent with extremely low water solubility and 
it was proven that the solubility in aqueous ethanol showed 70-fold increase [10]. Glibenclamide has 
extremely poor aqueous solubility and resulting low bioavailability, thus to improve its capability the 
complexes  with  2HP-β-CD  were  also  presented  [11].  The  values  of  stability  constants  of  
flutamide-2HP-β-CD  were  very  high  in  comparison  with  five  other  CDs  [12]  and  lower  for  the 
complexation of ketoconazole-2HP-β-CD [13]. 
In  the  last  years,  several  reviews  describing  the  use  of  CDs  in  food  processing  have  been  
published [14–16]. CDs may be used as a binding substance to flavors, fragrances, vitamins, as food 
additives  [14].  CDs  may  be  also  recommended  for  applications  in  food  technology  to  protect 
lipophylic food components that are sensitive to oxygen and light- or heat-induced degradation. CDs 
may be used as pharmaceuticals for controlled release of certain food constituents and to suppress 
unpleasant odors or tastes [15,16]. Again it was confirm that β-CD show higher binding constants than 
-complexes [15]. 
Recently, the solubility of two drug derivatives of anthranilic acid (the mefenamic acid, MEF, and 
meclofenamic  acid  sodium  salt,  MASS)  in  three  solvents—water,  ethanol  and  1-octanol—were 
investigated by us [17,18]. MEF is an anthranilic and indole acetic-type acid. It is a poorly soluble 
pharmaceutical, 0.17 ×  10
−4 mmol· dm
−3 at T = 298.15 K [19] or 0.87 ×  10
−4 mmol· dm
−3 at T = 298.15 K 
and pH between 3 and 6 [20]. An interesting analysis was provided for the solubility of MEF in water 
at T = 298.15 K influenced by the different excipients [20,21]. In conclusion it was stated that the 
mefanamic acid forms anionic dimers and trimers and excipients increase the solubility. The solubility 
of  MEF  in  ethanol  and  1-octanol  at  T  =  298.15  K  and  pH  7  was  36.9  mmol· dm
−3  and  
13.07 mmol· dm
−3, respectively [17]. A crystal structure of the inclusion complex of β-CD with MEF 
has already been determined by a combination of high-resolution synchrotron powder-diffraction data 
and molecular-mechanics calculations [22]. 
The  chosen  drugs,  and  especially  FLU  have  been  used  in  the  treatment  of  arthritis  and  other 
illnesses related to muscular-skeletal problems [23]. The influence of pH on the optical properties of Int. J. Mol. Sci. 2011, 12                       
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FLU in nanosystems was recently developed [24]. The influence of cyclodextrin and surfactants on 
micellar  systems  in  aqueous  solutions  and  the  fluorescence  of  mixtures  were  described  [25].  The 
solubility of FLU in water at T = 298.15 K is 2.38 ×  10
−2 mmol· dm
−3 [19]. 
In this study we have focused our attention on the inclusion of drug derivatives of anthranilic acid 
with 2HP-β-CD, a steroidal molecule with cavity size suitable for hosting the large molecules. To 
understand the character and properties of the association, we investigated the effect of 2HP-β-CD on 
aqueous solubility and we evaluated the stoichiometry and stability of the complexes. 
2. Results and Discussion  
2.1. Solvent Effect and Solution Equilibrium 
The absorption spectra of drugs depend on pH of the solution due to protonation/deprotonation of 
nitrogen atom in the drug structure. Figure 1 presents examples of the absorption spectra of three drugs 
at different pHs.  
Figure 1. Absorption spectra of different concentrations of drugs at T = 298.15 K and their 
calibration curves. (a) Mefemamic acid, phosphate buffer I (pH 7.0); (b) Mefemamic acid, 
phosphate buffer II (pH 2.0); (c) Niflumic acid, phosphate buffer I (pH 7.0); (d) Niflumic 
acid,  phosphate  buffer  II  (pH  2.0);  (e)  Flufenamic  acid,  phosphate  buffer  I  (pH  7.0);  
(f) Flufenamic acid, phosphate buffer II (pH 2.0).  
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The calibration curves are included in these figures. The absorption spectra were recorded in the 
range of 190–350 nm and for the calculation of 2HP-β-CD concentration the change of absorption was 
measured at 340 nm (pH 7.0), 195 nm (pH 2.0) for MEF; 245 nm (pH 7.0), and 250 nm (pH 2.0) for 
NIF and 255 nm (pH 7.0), and 225 nm (pH 2.0) for FLU, respectively. 
The  aqueous  solubility  of  the  studied  compounds  were  found  to  increase  almost  linearly  with  
2HP-β-CD concentration. The two exceptions are MEF and NIF at T = 298.15 K and pH = 2, for which 
the influence of 2HP-β-CD is linear but not very intensive (see Figure 2a and 2b). The solubility 
dramatically increases with an increase of pH and temperature (see Table 1).  
Figure 2. 2HP-β-CD influence on the drug solubility at different temperatures and pHs. 
Experimental points: () pH = 2 and T = 298.15 K; () pH = 2 and T = 310.15 K;  
() pH = 7 and T = 298.15 K; () pH = 7 and T = 310.15 K; Lines are drown to show the 
trends. (a) Mefenamic acid dependence; (b) Niflumic acid dependence; (c)  Flufenamic  
acid dependence. 
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Table 1. The solubility (C) in water at two temperatures and two pHs (buffer solutions), 
calculated values of solubility enhance ratio (R), calculated values of cyclodextrin-drug 
complex stability constants Ks and dissociation constants Kd. 
pH  T/K  CD/mM  R  Ks/M
−1  Kd∙10
3/M 
Mefenamic acid 
2 
298.15  0.001  6.4  539  1.86 
310.15  0.001  17.3  1627  0.62 
7 
298.15  0.155  4.6  383  2.61 
310.15  0.220  6.0  562  1.78 
Niflumic acid 
2 
298.15  0.698  1.3  26  38.9 
310.15  0.925  1.3  33  29.2 
7 
298.15  5.754  1.6  96  10.4 
310.15  8.171  1.5  82  12.2 
Flufenamic acid 
2 
298.15  0.006  31.0  3055  0.33 
310.15  0.015  19.0  1850  0.54 
7 
298.15  0.228  2.9  202  4.95 
310.15  0.298  3.0  218  4.59 
 
Solubility  enhance  ratio,  R,  was  calculated  as  a  drug  concentration  at  the  highest  cyclodextrin 
concentration with relation to drug concentration in the absence of cyclodextrin. Calculated values 
have been reported in Table 1. Solubility enhance ratio increases with an increase of temperature for 
MEF at pH = 2, 7, for NIF at pH = 2, and for FLU at pH = 2, 7 and slightly decreases with an increase 
of temperature for NIF at pH = 7. R decreases with an increase of pH for MEF and FLU, which 
demonstrates effects in drug release in the basic environment of intestinal part of the alimentary tract. 
The opposite effect is observed for NIF. The highest solubility enhance ratio, R is observed for FLU at 
pH = 2 (R = 31.0 at T = 298.15 K and R = 19.0 at T = 310.15 K) and MEF at pH = 2 (R = 17.3 at  
T = 310.15 K). In general, when the solubility of the drug is very low, the solubility enhance ratio, R is 
high. Substitution of hydroxyl groups surrounding the 2HP-β-CD rim by the hydroxypropyl group 
promotes the complex formation process for drug derivatives of anthranilic acid with polar carboxylic 
substituent. Perhaps the aromatic rings increase the 2HP-β-CD cavity dimensions and the carboxylic 
group stabilizing the outside hydrophilic groups and the binding of drug with 2HP-β-CD becomes 
more effective.  
It was shown for MEF that the phenyl moieties were located outside the β-CD cavity, and the N 
atom that links the two phenyl rings is situated at the secondary face of the CD macrocycle with a 
hydrogen bond to the G4 glucose unit of the neighboring β-CD molecule [25].  
2.2. Solvent Effect and Solution Equilibrium 
Measurements of cyclodextrin-drug complex stability constants Ks and dissociation constants Kd are 
very important since these values indicate changes in physicochemical properties of a compound upon Int. J. Mol. Sci. 2011, 12                       
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inclusion. Linear dependence of drug concentration to cyclodextrin concentration, with slope ratio 
below one usually assumes 1:1 ratio of complex.  
The stability constant, Ks, for complexes with 1:1 ratio is represented by: 
 
    C D
CD
s 
 K    (1)  
Where:  [D]  is  pure  drug  concentration,  [C]  is  pure  cyclodextrin  concentration,  and  [CD]  is 
concentration  of  drug-cyclodextrin  complexes  in  solution.  Complex  dissociation  constant,  Kd,  is 
represented by: 
s
d
1
K
K    (2)  
For  such  systems,  stability  constant  can  be  obtained  by  the  following  equation,  investigated 
previously by Higuchi and Connors, 1965 [25]: 
  slope 1
slope
0
1 : 1 s  
 
c
K K    (3)  
Calculated values are reported in Table 1. The solubility data indicate that the largest enhancement 
of  the  solubility  and  the  highest  stability  constant  values  were  obtained  for  FLU  at  
pH = 2 (Ks = 3055 M
−1, T = 298.15 K; Ks = 1850 M
−1, T = 310.15 K) and for MEF at pH = 2  
(Ks = 1627 M
−1, T = 310.15 K). These values suggest a relatively stable complex. The cavity of 
cyclodextrin  exhibits  a  hydrophobic  character,  whereas  the  exterior  is  strongly  hydrophilic.  The 
process of complexation of MEF by 2HP-β-CD is high at two pHs and two temperatures, which can be 
connected with the association between the guest molecule and cyclodextrin molecule in solution via 
the  two  methyl  groups  of  the  MEF  molecule  stabilized  by  the  carboxylic  group  outside  the 
cyclodextrin. The structure of the three investigated compounds is similar. Two methyl groups in the 
molecule of MEF decrease the solubility in water in comparison with fluorine atoms of NIF and FLU 
and increase the complexation. The only difference between the NIF and FLU is the nitrogen atom in 
one of the aromatic rings in NIF. For these two substances, the molar mass is close to the same, and as 
a consequence of the additional nitrogen atom in NIF molecule, the stability constants, Ks are lower 
than  those  for  FLU  at  two  pH  and  two  temperatures.  The  significant  differences  in  the  stability 
constants  for  different  drugs  at  various  pHs  and  temperatures  are  connected  to  a  different  drug 
ionization degree, which increases with lowering pH, and with consequently less affinity for neutral 
2HP-β-CD cavity. Data listed in Table 1 shows that at pH = 2, the FLU is almost fully ionized. A 
similar effect was observed for ketoconazole and flutamide with different CDs [13]. 
2HP-β-CD was found to be a more suitable complexating agent between four cyclodextrins for NIF, 
which was confirm by 
1H NMR, UV-vis spectroscopy, densimetry and calorimetry (at pH = 7.4 and  
T  =  298.15  K)  [26].  The  1:1  stoichiometry  of  the  2HP-β-CD/NIF  complexes  was  determined  by 
Terekhova et al. [27], Zielenkiewicz et al. [26] and Bogdan et al. [28].  
The phase solubility diagrams  and stability  constant  was presented for FLU at pH =  6.75 and  
T = 298.15 K by Mura et al. [29]. 
Our value of stability constant for NIF at pH = 7 is log Ks = 1.98, whereas from the calorimetric, 
densimetry, UV-vis, and 
1H NMR measurements at pH = 7.4 it is log Ks = 2.2, log Ks = 2.8, log Ks = 3.09 Int. J. Mol. Sci. 2011, 12                       
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and log Ks = 2.3, respectively (T = 298.15 K) [26]. The literature value at pH = 12 is log Ks = 2.53 [28] 
and at pH = 7 log Ks = 2.72 [30] (T = 298.15 K). For FLU our value of stability constant at pH = 7 is 
log Ks = 2.30 and the literature value, obtained also from the phase-solubility diagrams at similar  
pH = 6.75 is log Ks = 2.36 [29] (T = 298.15 K). We can conclude at this moment that not only the 
temperature and pH but also the method of developing the stability constant is important. 
Thermodynamic parameters of reactions i.e. the free energy change (ΔG), the enthalpy change (ΔH) 
and the entropy change (ΔS), can be obtained from the temperature dependence of stability constant [2]. 
Calculated values are reported in Table 2. 
1 : 1 ln R K T G      (4)  
 


 

   
  


 


2 1
1 2
1
2
R 303 . 2
log
T T
T T H
K
K
  (5)  
S T H G        (6)  
Table 2. Thermodynamic parameters of reactions i.e., the free energy change (ΔG), the 
enthalpy  change  (ΔH)  and  the  entropy  change  (ΔS)  at  T  =  298.15  K  and  pH  =  7  
(buffer solution). 
Drug  ΔG 
/(kJ· mol
−1) 
ΔH 
/(kJ· mol
−1) 
ΔS 
/(J· mol
−1· K
−1) 
MEF  −14.7  −24.6  −33.0 
NIF  −11.3  −10.0  4.3 
FLU  −19.9  −4.9  50.2 
 
The thermodynamic parameters of the inclusion process estimated from the temperature dependence 
of  the  stability  constants  using  van’t  Hoff  relation  show  different  values  of  enthalpy,  which  is 
complexation parameter control. The highest value of enthalpy was observed for FLU (−4.9 kJmol
−1) 
in  comparison  with  the  two  other  drugs  (−10.0  kJmol
−1  and  −24.6  kJmol
−1  for  NIF  and  MEF, 
respectively). Negative values of ΔH and ΔS indicate that the van der Waals forces are responsible for 
the  complexation  process  (observed  only  for  MEF).  In  contrast,  a  huge  hydrophobic  interaction 
appears to contribute to the association of 2HP-β-CD and FLU, for which the entropy is high and 
positive (50.2 Jmol
−1K
−1). The lower value of positive entropy for NIF indicates also hydrophobic 
interactions.  The  only  difference  between  those  two  structures  is  aromatic  nitrogen  in  the  NIF 
structure, which increases hydrophobic interactions with 2HP-β-CD. 
For the sake of comparison, only the free energy change (ΔG) of the reaction of complexation for 
NIF is similar to the literature value: ours is ΔG = −11.3 kJmol
−1 (T = 298.15 K and pH = 7); the 
literature value is ΔG = −12.3 kJmol
−1 (T = 298.15 K and pH = 7.4) [26]. The high negative value of 
enthalpy was obtained in previous work (−20.1 kJmol
−1) and negative entropy [26]. These results were 
concluded from the densimetry and 
1H NMR measurements. Int. J. Mol. Sci. 2011, 12                       
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3. Experimental Section  
3.1. Materials and Instruments 
Studied drugs were obtained from Sigma Aldrich, i.e., mefenamic acid (CAS Registry No. 61-68-7; 
≥0.99 mass fraction purity), niflumic acid (CAS Registry No. 4394-00-7; ≥0.99 mass fraction purity), 
flufenamic  acid  (CAS  Registry  No.  530-78-9;  ≥0.99  mass  fraction  purity).  The  drugs  were  used 
without  purification  and  were  used  as  powder  or  small  crystals.  2-Hydroxypropyl-β-cyclodextrin 
(2HP-β-CD) was delivered by ACROS Organics (CAS Registry No.128446-35-5; ≥0.97 mass fraction 
purity). Water used as a solvent was twice distilled, degassed and filtered with Milipore Elix 3. The 
buffers  solution,  were  prepared  from  substances  delivered  by  POCH,  i.e.,  potassium  dihydrogen 
phosphate (CAS Registry No. 7758-11-4; ≥99.5% mass fraction purity), disodium hydrogen phosphate 
CAS  Registry  No.  7558-80-7;  ≥99.5%  mass  fraction  purity),  hydrochloric  acid  (CAS  Registry  
No. 7647-01-0; ≥35% mass fraction purity). All drugs were filtrated twice with Schott funnel with  
4 μm pores. The names, abbreviations, structures and molar masses of the drugs and 2HP-β-CD are 
given in Table 3.  
Table 3. Investigated compounds: name, abbreviation, structure, and molar mass. 
Name of compound/ 
abbreviation 
Structural formula  M/g ·  mol
−1 
Mefenamic acid/MEF 
NH
O OH
CH3
CH3
 
241.30 
Niflumic acid/NIF 
N
NH
O OH F
F
F
 
282.22 
Flufenamic acid/FLU 
NH
O OH F
F
F
 
281.23 
(2-Hydroxypropyl)-β-
cyclodextrin 
 
average ~1.460 
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The UV-Vis spectrophotometer (Perkin–Elmer Life and Analytical Sciences, Shelton, USA) was 
used  to  determine  the  2HP-β-CD  influence  on  drug  solubility.  Maximum  drug  concentration  was 
measured at different cyclodextrins concentrations, temperatures and pHs. Samples contained buffer 
solution with pH 7 or 2, 2HP-β-CD in different concentrations, i.e., 0, 1, 2, 4, 7 or 10 mmol∙dm
-3 and 
drug in excess. Samples were thermostated and mixed for 20 hours and then left for 4 hours for 
separation. The uncertainties of the temperature measurements were judged to be 0.1 K. Absorbance of 
each sample was measured with the UV-vis spectrophotometer.  
3.2. Preparation of Solutions 
The stability constants were determined by the measurements of the concentration of the drug in the 
sample  as  a  function  of  the  cyclodextrin  concentration.  Such  a  method  is  usually  called  ―Phase 
solubility study‖ [31]. In this method complex stability constants are calculated from the obtained 
solubility data using  a spectophotometric method. As a reference sample, the buffer + 2HP-β-CD 
solutions  were  used.  Two  buffers  were  prepared  (mol  concentration)  i.e.,  potassium  dihydrogen 
phosphate (0.008), disodium hydrogen phosphate (0.008; buffer, pH = 7.0), potassium dihydrogen 
phosphate (0.05), hydrochloric acid (0.05, buffer, pH = 2.0). Samples were scanned with a scan step of 
1 nm from 650 to 190 nm. Measurements at pH = 10 were not performed in all systems, because of the 
necessity  of  using  too  high  drug  concentrations  and  because  of  problems  with  separation  of  
two phases. 
4. Conclusions  
The effect of 2HP-β-CD on the spectrophotometric behavior of three drugs, MEF, NIF and FLU 
was developed. The phase solubility diagram of the drugs in buffer aqueous solutions showed that the 
solubility  of  drugs  increased  linearly  as  a  function  of  2HP-β-CD  concentration.  The  increase  in 
solubility can be attributed to the formation of inclusion complexes between drug and 2HP-β-CD 
characterized by greater solubilities than that of drug alone. From the results it may be concluded that 
2HP-β-CD forms 1:1 inclusion complexes with high stability and high stability constants, especially 
for FLU at pH = 2 and T = 298.15 K and T = 310.15 K as well as for MEF at pH = 2 and T = 310.15 K. 
The significant differences in stability constants at various pH values are connected with different drug 
ionization degree and various affinities for 2HP-β-CD cavity. The van der Waals forces coming from 
two methyl groups in MEF play an important role in the complex formation. Overall, the findings from 
this study strongly support the possibility of using 2HP-β-CD to significantly enhance the solubility of 
three drugs, mefenamic acid, niflumic acid and flufenamic acid in aqueous systems and enlarge the 
range of application of these anti-inflammatory pharmaceuticals. 
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